I-Mab
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Xi-Yong Fu
- Full Time Employees
- 32
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- New Bund Center Rockville United States of America 200124
- IPO Date
- Jan 17, 2020
- CIK
- 0001778016
- Website
- i-mabbiopharma.com
- Similar Companies
- Business
- I-Mab (NASDAQ: IMAB), a clinical-stage U.S.-based biotechnology company founded in 2014 and headquartered in Rockville, Maryland, discovers, develops and seeks to commercialize novel biologics focused on immuno-oncology and autoimmune diseases; its lead product candidate is givastomig, a Claudin 18.2 x 4-1BB bispecific antibody in Phase 1b trials for Claudin 18.2-positive gastric cancers and solid tumors; additional pipeline assets include ragistomig, a bispecific antibody in Phase 1 for solid tumors, uliledlimab, a CD73 neutralizing antibody paused in development, felzartamab (TJ202), an anti-CD38 antibody with a BLA submitted in China for relapsed/refractory multiple myeloma and in trials for autoimmune diseases including IgAN, eftansomatropin alfa (TJ101), a long-acting growth hormone with Phase 3 completed for pediatric growth hormone deficiency, and olamkicept (TJ301), an IL-6 blocker in Phase 2 for ulcerative colitis and autoimmune disorders. The company operates primarily in the United States with a streamlined team of approximately 32 employees and conducts global clinical trials targeting cancer patients and those with autoimmune conditions. Recent strategic changes include the divestiture of its China assets and operations in 2024 to transition fully to a U.S.-centric biotech; the acquisition of Bridge Health in July 2025 for $3 million upfront plus milestones to secure upstream IP rights for the Claudin 18.2 antibody in givastomig, eliminating future royalties and milestone obligations; the pause of uliledlimab development earlier in 2025 with associated workforce reductions of 27%; and the launch of subsidiary Visara in October 2025 with $37 million funding to develop VIS-101, an ophthalmology asset acquired from AffaMed Therapeutics for serious eye disorders.
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know
What Makes IMab (IMAB) a New Buy Stock
I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market
Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
I-Mab to Participate in September Investor Conferences
Everest Medicines Expands Strategic Investment in I-MAB
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross